Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,415.92 -8.93 -0.05%
S&P 500 1,864.07 1.76 0.09%
NASDAQ 4,095.08 8.86 0.22%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

RBCC Poised To Gain Share Of $142 Billion Market



  RBCC Poised To Gain Share Of $142 Billion Market

Business Wire

NOKOMIS, Fla. -- June 5, 2013

With innovative drug therapies gaining in popularity, Rainbow BioSciences,
LLC, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), continues
its partnering talks with a transdermal patch company as it readies to take a
share of the booming $142 billion U.S. drug delivery market.

Industry insiders forecast the transdermal delivery market could rise as high
as $31.5 billion by 2015 and will only continue to grow as it is used for many
treatments, including nicotine addiction and Parkinson’s disease.

Transdermal patches have gained in popularity in recent years and offer major
advantages to patients. They are easy to use, dispense the medicine gradually
and to a designated area, last longer and reduce side effects, among other
gains for patients.

“Personalized medicine is the future,” RBCC CEO Patrick Brown said. “This is
an incredible breakthrough for any patient who doesn’t want to take pills or
is afraid of needles. The transdermal patch empowers the patient to medicate
on their schedule. It is perfect for our growing elderly population.”

RBCC has formed a biotech subsidiary, Rainbow BioSciences, to market and
develop new medical and research technology innovations to compete alongside
companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc.
(NASDAQ: BIIB), Abbot Laboratories (NYSE: ABT) and Amgen, Inc. (NASDAQ: AMGN).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB: RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visit www.RainbowBioSciences.com. For investment information and
performance data, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words “believes,” “expects,” “anticipate” or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone’s past success, either financial or strategic, is no guarantee of
success. This news release speaks as of the date first set forth above and the
Company assumes no responsibility to update the information included herein
for events occurring after the date hereof.

Contact:

Rainbow Coral Corp.
Patrick Brown, 850-269-7230
President and CEO
info@rainbowcoral.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement